Replimune Group, Inc. Profile Avatar - Palmy Investing

Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against canc…

Biotechnology
US, Woburn [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of REPL's Analysis
CIK: 1737953 CUSIP: 76029N106 ISIN: US76029N1063 LEI: - UEI: -
Secondary Listings
REPL has no secondary listings inside our databases.